Indian journal of cancer最新文献

{"title":"The journey continues: Acknowledging the past, welcoming the future.","authors":"Vinay Deshmane","doi":"10.4103/ijc.ijc_663_26","DOIUrl":"https://doi.org/10.4103/ijc.ijc_663_26","url":null,"abstract":"","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"63 2","pages":"113"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Boswellia serrata in cerebral radiation necrosis: Comments on a recent study.","authors":"Raju Das, Saurabh Samdariya","doi":"10.4103/ijc.ijc_399_26","DOIUrl":"10.4103/ijc.ijc_399_26","url":null,"abstract":"","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"204"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital health information: Validity and reliability check of Hindi YouTube videos on cervical cancer.","authors":"Nibha Sinha","doi":"10.4103/ijc.ijc_238_26","DOIUrl":"10.4103/ijc.ijc_238_26","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is a leading cause of cancer-related deaths in women in low-and middle-income countries. Awareness plays a crucial role in early diagnosis and prevention. Among social media platforms, YouTube offers extensive health awareness content, including information on cervical cancer. However, the validity, reliability, and usefulness of this content are not known. This study aimed to evaluate the quality and validity of widely viewed Hindi YouTube videos on cervical cancer.</p><p><strong>Methods: </strong>YouTube was searched using the term \"cervical cancer-Hindi.\" The 50 most-viewed Hindi videos were manually coded and statistically analyzed. Reliability was assessed using the DISCERN scale, while quality, credibility and usefulness were evaluated using the Journal of the American Medical Association (JAMA) and Global Quality Score (GQS) tools. Two experienced public health researchers independently rated the videos, and their agreement correlation scores were calculated. Videos from professionals, news organizations, and individuals were compared.</p><p><strong>Results: </strong>Among the 50 videos, 78% were uploaded by professionals ( N = 39), 14% by news organizations ( N = 7), and 8% by individuals ( N = 4). The DISCERN median 36.50 (31-42), GQS median 8.00 (6.00-10.00), and JAMA median 6.00 (4.00-8.00) were reported. Observers' agreement for JAMA, GQS, and DISCERN was statistically significant. However, no significant differences were observed between professionals, individuals, and news organizations, or between genders and content types.</p><p><strong>Conclusion: </strong>Valid, reliable, and good-quality cervical cancer videos are available on YouTube and widely viewed. However, as no creator type showed significantly better quality, more efforts by professionals and news organizations are needed to enhance video reliability and awareness outcomes.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"160-165"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Second autologous hematopoietic stem cell transplantation in multiple myeloma.","authors":"Disha Kakkar, Vivek Mohan, Hamza Dalal, Subhaprakash Sanyal, Rahul Naithani","doi":"10.4103/ijc.ijc_50_26","DOIUrl":"10.4103/ijc.ijc_50_26","url":null,"abstract":"<p><strong>Background: </strong>High-dose melphalan followed by autologous stem cell transplantation (ASCT) is standard in multiple myeloma (MM), but relapse remains inevitable. Second ASCT2 is a salvage option for selected patients with durable remission after ASCT1. Reports from the Asia-Pacific region are limited.</p><p><strong>Methods: </strong>This retrospective study included six patients with relapsed MM who underwent ASCT2 between 2012 and 2025. Demographics, treatment characteristics, toxicity, engraftment, and outcomes were analyzed. All patients underwent fresh stem cell mobilization with granulocyte colony-stimulating factor and plerixafor without cryopreservation.</p><p><strong>Results: </strong>The median age at ASCT2 was 61 years (range, 47-65 years). The median interval between ASCT1 and ASCT2 was 66 months (range, 31-123 months). Two patients achieved partial remission (PR), 1 achieved very good partial remission (VGPR), and 3 achieved complete remission (CR) before ASCT2. Four patients received melphalan 140 mg/m² and 2 received melphalan 200 mg/m² for ASCT2. The median CD34⁺ cell dose infused during ASCT2 was 2.54 × 10⁶/kg (range, 1.42-21 × 10⁶/kg). Febrile neutropenia developed in 4 patients but was easily controlled with empiric antibiotics. Neutrophil recovery occurred at a median of 11 days (range, 10-14 days), and platelet recovery at 13 days (range, 12-15 days). Hospital stay duration ranged from 15 to 22 days, with a median of 18.5 days. There was no transplant-related mortality. The median follow-up of the study cohort was 28.5 months (range, 1-47 months). Two patients died at 35 and 47 months post-ASCT2, respectively, due to progressive disease. One patient was lost to follow-up after the second bone marrow transplant. Three patients remain alive and in sustained remission.</p><p><strong>Conclusion: </strong>ASCT2 is a feasible salvage strategy in selected Indian patients with MM, yielding favorable outcomes with acceptable toxicity.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"186-190"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer research in India: Proceedings of an expert consensus panel.","authors":"Arvind Krishnamurthy, Krithiga Shridhar, Ravi Mehrotra, Sharmila Pimple, L S Shashidhara, Suveera Dhup, M Vijayakumar","doi":"10.4103/ijc.ijc_151_25","DOIUrl":"10.4103/ijc.ijc_151_25","url":null,"abstract":"<p><strong>Abstract: </strong>We conducted an \"Expert Consensus Panel\" with transdisciplinary experts to deliberate on a 'Weakness, Opportunities, Threats, and Strengths' analysis with Underlying Planning for cancer research in India, to envision a way forward. The panel brought together leading experts from India to deliberate on population, clinical, and molecular research priorities in cancer. The deliberations focused on specific approaches necessary to scale up context-specific cancer research, while proposing a roadmap for the future integration of population science, clinical research and trials, and molecular research, including genomics, with the healthcare system for clinical translation and policy implementation.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"209-211"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of a novel tongue-sparing intraoral prosthesis for radiation therapy in a head and neck patient: A case report.","authors":"Vikas K Pandey, Anusheel Munshi, Asha Maria","doi":"10.4103/ijc.ijc_204_24","DOIUrl":"10.4103/ijc.ijc_204_24","url":null,"abstract":"<p><strong>Abstract: </strong>We designed an indigenous novel tongue-sparing intraoral prosthesis (TS-IOP) to minimize tongue toxicity in a 58-year-old patient with submental soft tissue sarcoma. We initially performed radiotherapy planning computed tomography (CT) using an intraoral prosthesis (IOP) to reduce the dose to the hard palate. However, IOP-induced tongue compression increased the oral tongue dose during radiotherapy planning. Therefore, we developed a TS-IOP that separated the hard palate from the floor of the mouth without compressing the tongue, thereby minimizing radiation exposure to the oral tongue. Upper and lower jaw dental impressions were obtained on a single wax sheet, and customized wax bolus sheets were prepared according to the dental impressions and mouth opening. The bolus was made U-shaped and hollow at the center to prevent tongue compression. Radiotherapy planning CT was subsequently performed using the TS-IOP and a head-and-neck thermoplastic mask. The TS-IOP achieved a lower radiation dose to the oral tongue while maintaining adequate target coverage. This novel prosthesis may be useful for lesions involving the floor of the mouth or submental region by keeping the oral tongue outside the high-dose region. Further clinical validation in larger cohorts is warranted.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"200-203"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148989839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Finnish founder population and MLH1 mutations in hereditary colorectal cancer.","authors":"Nirmal Raj Rajaram, Paramjot Kaur","doi":"10.4103/ijc.ijc_415_26","DOIUrl":"10.4103/ijc.ijc_415_26","url":null,"abstract":"<p><strong>Abstract: </strong>Identifying hereditary colorectal cancer genes is historically complicated by genetic heterogeneity. Founder populations simplify genetic architecture through reduced allelic diversity and extended linkage disequilibrium. This write-up explores how Finland's unique demographic history, driven by geographic isolation and severe population bottlenecks, established the distinct \"Finnish disease heritage.\" In the 1990s, this regional homogeneity proved instrumental in successfully mapping recurrent germline MLH1 (MutL Homolog 1) founder mutations in Lynch syndrome.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"114-119"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of perineural invasion and histopathological features/clinical outcomes for carcinoma oral cavity: An analysis of 781 patients.","authors":"Nikhil Kalyani, Parth Paatni, Aastha Maini, Bharat Bhosale, Ashay Karpe, Farhana Girkar, Saurabh Chalke, Rakesh Katna","doi":"10.4103/ijc.ijc_471_24","DOIUrl":"https://doi.org/10.4103/ijc.ijc_471_24","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the prognostic impact of perineural invasion (PNI) on oncological outcomes in oral cavity carcinoma patients.</p><p><strong>Methods: </strong>Chart review of 781 patients undergoing surgery for oral cavity carcinoma between 2013 to 2021 was done. All patients underwent surgery (per primum/post neoadjuvant chemotherapy) followed by adjuvant treatment as per histopathological report.</p><p><strong>Results: </strong>There were 653 male patients (83%) and the median age of the cohort was 48 years. Six hundred and thirty-two (80.8%) patients had locally advanced stage (III/IV). Three hundred and forty (44%) patients had PNI reported. PNI positivity correlated with higher pT stage, pN stage, overall stage and poor differentiation. Median follow-up was 51 months. At last follow-up, 571 patients (73%) were alive, of which 527 were disease free. Incidence of distant metastasis was significantly higher in patients having PNI (25% versus 13%, P = 0.001). On univariate analysis, patients with PNI-positive disease had significantly worse 5-year disease-free survival (DFS) (56% versus 68%, P = 0.001), locoregional control (LRC) (62% versus 72%, P = 0.001), and overall survival (OS) (57% versus 75%, P = 0.001) as compared to patients with PNI-negative disease. On multivariate analysis, PNI was significant factor only for OS ( P = 0.05), not for DFS ( P = 0.152) or LRC ( P = 0.174). For PNI-positive cohort, patients with perinodal extension had poor OS ( P = 0.01).</p><p><strong>Conclusion: </strong>PNI-positive disease had poor outcomes despite aggressive multimodality treatment. PNI positivity correlated with higher pT stage, pN stage, overall stage and poor differentiation. PNI may be considered an independent prognostic factor for OS in oral cavity cancers and should be evaluated further in a randomized controlled setting. Added presence of perinodal extension defines poor outcomes. Sub-classification of PNI may be tested for determining impact on outcomes.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"63 2","pages":"147-152"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review-based investigation on cancer statistics 2022: India at a glance.","authors":"Sukhjot Kaur, Zohra Khatoon","doi":"10.4103/ijc.ijc_626_24","DOIUrl":"10.4103/ijc.ijc_626_24","url":null,"abstract":"<p><strong>Abstract: </strong>This article offers a comprehensive analysis and updates using GLOBOCAN 2022, Cancer Atlas, National Cancer Registry Programme 2022, and many more available sources for information on cancer incidence and deaths in 2022 and their projections for 2025. As per reports, an estimated 20 million new instances of skin cancer, including non-melanoma cases, were reported globally, with 9.7 million of those cases resulting in fatalities and poor health. A cursory look at the Indian data reveals that the nation experiences over 1.4 million new instances of cancer each year, translating into 9 lakh fatalities. According to estimates, breast cancer has overtaken all other cancers and is now the most common cancer in the nation, accounting for 1.9 lakh (about 13.6%) of new cases. Cancers of the lip, oral cavity, and cervix uteri account for 10.2% and 9.0% of new cases, respectively. It was also discovered that breast cancer ranked highest in terms of mortality, accounting for about 98,337 fatalities (10.7%). The most common malignancies detected in males and women, respectively, were lip, oral cavity, and breast cancers (both cases and deaths). In 2025, it is also anticipated that the number of cases of lung and breast cancer will be 81,219 for males and 2,32,832 for females, respectively. Between 2015 and 2025, there will likely be a 27.7% rise in cancer cases across every site when taken into account. Given the likelihood that cancer incidence and deaths will rise in the future, attention must be paid to the factors that contribute to the disease to improve health and well-being.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"63 2","pages":"120-133"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CRISPR/Cas in gynecologic cancers: A review of experimental and therapeutic applications.","authors":"Edelbert A Almeida, Madhav Arora, Mohit Mehndiratta, Rachna Agarwal","doi":"10.4103/ijc.ijc_14_25","DOIUrl":"10.4103/ijc.ijc_14_25","url":null,"abstract":"<p><strong>Abstract: </strong>Gynecological malignancies-including cervical, ovarian, and endometrial cancers-remain a major global health challenge, contributing significantly to cancer-related morbidity and mortality among women. Despite advances in conventional treatments such as surgery, chemotherapy, radiotherapy, and immunotherapy, issues such as drug resistance, tumor recurrence, and limited efficacy in advanced-stage disease necessitate novel therapeutic strategies. The emergence of CRISPR/Cas-based genome editing has revolutionized cancer research by enabling precise, efficient, and programmable modifications of specific genomic loci. In gynecologic oncology, CRISPR/Cas systems have been employed to dissect oncogenic mechanisms, identify therapeutic targets, and develop innovative treatment modalities. In cervical cancer, CRISPR-mediated targeting of HPV E6 and E7 oncogenes has shown potential in restoring tumor suppressor pathways and enhancing chemosensitivity. In ovarian cancer, gene editing has been used to modulate chemoresistance, tumor angiogenesis, and metastasis through the knockout of key regulators such as DNMT1, EGFL6, and BRCA1/2. Similarly, in endometrial cancer, CRISPR tools have elucidated mechanisms of hormonal resistance and facilitated the development of in vivo models via somatic gene editing. This review highlights recent advances in the application of CRISPR/Cas technology to gynecologic malignancies, discussing its potential as both a therapeutic and research platform while acknowledging current limitations and translational hurdles.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"63 1","pages":"1-8"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}